Previous 10 | Next 10 |
2023-05-11 09:54:06 ET Reneo Pharmaceuticals press release ( NASDAQ: RPHM ): Q1 GAAP EPS of -$0.60 in-line. Raised $68.3 million in gross proceeds from a concurrent public offering and private placement in May 2023 For further details see: Reneo Pharmaceuticals G...
Completed enrollment of the pivotal STRIDE study; topline results anticipated 4Q 2023 Raised $68.3 million in gross proceeds from a concurrent public offering and private placement IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clini...
2023-05-04 10:00:25 ET Gainers: Soligenix ( SNGX ) +117% . ZimVie ( ZIMV ) +27% . Lantheus ( LNTH ) +14% . MiNK Therapeutics ( INKT ) +16% . Reviva Pharmaceuticals ( RVPH ) +10% . Losers: Sensus Healthcare ( SRTS ...
2023-05-04 06:16:49 ET Clinical-stage pharmaceutical company, Reneo Pharmaceuticals ( NASDAQ: RPHM ) prices underwritten public offering of ~6.88M shares at a public offering price of $8.00 per share. Aggregate gross proceeds of ~$55M. Underwriters have a 30-day option...
2023-05-04 02:08:35 ET Summary Reneo is small and relatively undercovered. It has positive data from lead and only asset mavodelpar in early trials. Reneo could get interesting quickly. Reneo Pharmaceuticals ( RPHM ) develops treatments for mitochondrial diseases...
IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Reneo) (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the pricing of its prev...
2023-05-03 16:20:52 ET Reneo Pharmaceuticals ( NASDAQ: RPHM ) has commenced an underwritten public offering of its shares of common stock, the company said on Wednesday. Shares -10.8% at $8.80 after hours. Reneo intends to grant the underwriters a 30-day opti...
IRVINE, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Reneo) (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that it has commenced a...
2023-03-27 09:38:16 ET Reneo Pharmaceuticals press release ( NASDAQ: RPHM ): Q4 GAAP EPS of -$0.56. Research and development (R&D) expenses were $10.4 million during the fourth quarter of 2022, compared to $7.1 million for the same period in 2021. General and admin...
IRVINE, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the quar...
News, Short Squeeze, Breakout and More Instantly...
Reneo Pharmaceuticals Inc. Company Name:
RPHM Stock Symbol:
NASDAQ Market:
Reneo Pharmaceuticals Inc. Website:
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sal...
MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) with privately held OnKure, Inc. (“OnKure”) in a stock-for-stock transaction under which ...
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide fun...